Skip to main content
SpringerLink
Log in

Immunotherapy for Graves’ orbitopathy: Easy enthusiasm, but let’s keep trying

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bartalena L, Marcocci C, Pinchera A. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.

    CAS  PubMed  Google Scholar 

  2. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003, 24: 802–35.

    Article  CAS  PubMed  Google Scholar 

  3. Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295–301.

    Article  CAS  PubMed  Google Scholar 

  4. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves’ ophthalmopathy. J Endocrinol Invest 2005, 28: 469–78.

    Article  CAS  PubMed  Google Scholar 

  5. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves’ ophthalmopathy on quality of life. J Endocrinol Invest 2004, 27: 259–64.

    Article  CAS  PubMed  Google Scholar 

  6. Tanda ML, Bartalena L. Currently available somatostatin analogs are not good for Graves’ orbitopathy. J Endocrinol Invest 2006, 29: 389–90.

    Article  CAS  PubMed  Google Scholar 

  7. Garrity JA, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006, 142: 147–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 237–45.

    Article  CAS  PubMed  Google Scholar 

  9. Starkey K, Heufelder A, Baker G, et al. Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003, 88: 55–9.

    Article  CAS  PubMed  Google Scholar 

  10. Mimura LY, Villares SMF, Monteiro MLR, Guazzelli IC, Bloise W. Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/coonnective tissues is increased during the active stage of Graves’ ophthalmopathy. Thyroid 2003, 13: 845–50.

    Article  CAS  PubMed  Google Scholar 

  11. Feldon SE, Park DJJ, O’Loughlin CW, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 2005, 46: 3913–21.

    Article  PubMed  Google Scholar 

  12. Drexhage HA. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves’ disease? Endocrinology 2005, 147: 9–12.

    Article  Google Scholar 

  13. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295: 2275–85.

    Article  CAS  PubMed  Google Scholar 

  14. Gudbrandsdottir S, Larsen R, Sorensen LK, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004, 22: 118–24.

    CAS  PubMed  Google Scholar 

  15. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye 2005, 19: 1286–9.

    Article  CAS  PubMed  Google Scholar 

  16. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6: 859–66.

    Article  CAS  PubMed  Google Scholar 

  17. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20. What do B-cells do? Clin Immunol 2005, 117: 207–13.

    Article  CAS  PubMed  Google Scholar 

  18. Traullè C, Coiffier BB. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol 2005, 1: 297–306.

    Article  PubMed  Google Scholar 

  19. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005, 64: 55–7.

    Article  Google Scholar 

  20. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L. The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. EurJ Endocrinol 2006, 154: 623–32.

    Article  Google Scholar 

  21. Hasselbach HC. B cell depletion with rituximab — a targeted therapy for Graves’ disease and autoimmune thyroiditis. Immunol Lett 2003, 88: 85–6.

    Article  Google Scholar 

  22. El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L. Successful B lymphocyte depletion with rituximab in a patient with recurrent Graves’ disease and severe ophthalmopathy. Thyroid 2005, 15: S28.

    Google Scholar 

  23. Salvi M, Vannucchi G, Campi I, et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154: 511–7.

    Article  CAS  PubMed  Google Scholar 

  24. Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002, 13: 280–7.

    Article  CAS  PubMed  Google Scholar 

  25. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352: 2598–608.

    Article  CAS  PubMed  Google Scholar 

  26. O’Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci 2006, 11: 1620–35.

    Article  PubMed  Google Scholar 

  27. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349: 1907–15.

    Article  CAS  PubMed  Google Scholar 

  28. Alegre M-L, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 2006, 12: 149–60.

    Article  CAS  PubMed  Google Scholar 

  29. Ravandi F, O’Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005, 5: 39–51.

    Article  CAS  PubMed  Google Scholar 

  30. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005, 10: 79–93.

    Article  CAS  PubMed  Google Scholar 

  31. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354: 1601–5.

    Article  Google Scholar 

  32. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 449–52.

    CAS  PubMed  Google Scholar 

  33. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63: 1062–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50: 1761–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrinology, Department of Clinical Medicine, University of Insubria, Varese, Italy

    L. Bartalena & M. L. Tanda

Authors
  1. L. Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartalena, L., Tanda, M.L. Immunotherapy for Graves’ orbitopathy: Easy enthusiasm, but let’s keep trying. J Endocrinol Invest 29, 1012–1016 (2006). https://doi.org/10.1007/BF03349216

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349216

Keywords

Search

Navigation